Sun.Feb 11, 2024

article thumbnail

Hydromorphone hydrochloride preconditioning combined with postconditioning attenuates myocardial ischemia/reperfusion injury in rats by improving mitochondrial function and activating the PI3K/Akt signaling pathway

Chemical Biology and Drug Design

Hydromorphone hydrochloride (HH) attenuates myocardial ischemia/reperfusion injury in rats by by promoting mitochondrial biogenesis to improve mitochondrial function and reduce oxidative stress, and activating the PI3K/Akt signaling pathway. HH preconditioning combined with postconditioning showed optimal efficacy. Abstract Thrombolytic therapy or percutaneous coronary intervention for myocardial infarction often cause myocardial ischemia/reperfusion injury (MIRI) and poor prognosis of patients.

article thumbnail

Which pharmaceutical drugs have the most drug patents in Peru?

Drug Patent Watch

This chart shows the drugs with the most patents in Peru. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.… The post Which pharmaceutical drugs have the most drug patents in Peru? appeared first on DrugPatentWatch - Make Better Decisions.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Going Beyond the Sitecore Mentor Program: Pushing Boundaries with Exclusive Mentorship

Perficient: Drug Development

At this time many of you may have heard about the official Sitecore Mentor Program , run by Nicole Montero from the Sitecore Technical Marketing Team. Mentor Program celebrates its second year with a significant growth of positive outcomes and success stories from both mentors and mentees. I am going to share mine with you, and this one is special. As I sit down to reflect on my journey as a mentor over the past year, I am filled with a sense of accomplishment.

article thumbnail

Marijuana: Top Ten Reasons for Descheduling, Rescheduling or Not

FDA Law Blog: Biosimilars

By Larry K. Houck — With apologies to David Letterman, who introduced the first Top Ten List on Late Night with David Letterman on September 18, 1985, we present “Marijuana: Top Ten Reasons for Descheduling, Rescheduling or Not.”* The wide range of assertions supporting or opposing Health and Human Services’ (“HHS’”) recommendation that the Drug Enforcement Administration (“DEA”) reschedule cannabis federally from schedule I to schedule III would lead an outsider to conclude that commenters are

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Another Reason Why The FDA, Not Litigants, Approves Products

Drug & Device Law

We’ve blogged several times already about the Alliance for Hippocratic Medicine v. FDA litigation that is now before the Supreme Court. Briefly, a Texas District Court , in a decision that we’ve already described as “results-driven and shoddy,” purported to invalidate more than 20 years of FDA regulation – back to and including the original 2000 agency approval – of the abortifacient drug mifepristone, which would have had the effect of immediately removing from the market nationwide the safe

FDA 59